Get the Stockscreener App
1.76
7.98%
0.13
After Hours:
1.76
Bioatla Inc stock is traded at $1.76, with a volume of 606.85K.
It is up +7.98% in the last 24 hours and down -0.56% over the past month.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
See More
Previous Close:
$1.63
Open:
$1.64
24h Volume:
606.85K
Relative Volume:
0.68
Market Cap:
$83.38M
Revenue:
-
Net Income/Loss:
$-123.46M
P/E Ratio:
-0.6771
EPS:
-2.5993
Net Cash Flow:
$-104.11M
1W Performance:
+6.02%
1M Performance:
-0.56%
6M Performance:
-48.84%
1Y Performance:
+3.53%
1-Day Range:
$1.61
$1.76
1-Week Range:
$1.55
$1.76
52-Week Range:
$1.14
$4.02
Bioatla Inc Stock (BCAB) Company Profile
Name
Bioatla Inc
Sector
Industry
Phone
858-558-0708
Address
11085 TORREYANA ROAD, SAN DIEGO
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-15-22 | Initiated | JMP Securities | Mkt Outperform |
| May-05-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-21-22 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Jun-28-21 | Initiated | ROTH Capital | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | BTIG Research | Buy |
| Jan-11-21 | Initiated | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | JP Morgan | Overweight |
| Jan-11-21 | Initiated | Jefferies | Buy |
View All
Bioatla Inc Stock (BCAB) Latest News
BioAtla Inc (BCAB)’s financial ratios: A comprehensive overview - The Dwinnex
A new trading data show BioAtla Inc (BCAB) is showing positive returns. - SETE News
XTX Topco Ltd Trims Stock Position in BioAtla, Inc. (NASDAQ:BCAB) - Defense World
Scion Asset Management LLC Purchases Shares of 633,959 BioAtla, Inc. (NASDAQ:BCAB) - Defense World
Wall Street SWOT: BioAtla stockInnovative cancer therapy faces pivotal year - Investing.com
BCAB’s valuation metrics: A comprehensive analysis - US Post News
Scion Asset Management LLC Purchases Shares of 633,959 BioAtla, Inc. (NASDAQ:BCAB) - MarketBeat
Century Therapeutics (NASDAQ:IPSC) & BioAtla (NASDAQ:BCAB) Financial Comparison - Defense World
BioAtla and Context Therapeutics Forge Strategic Agreement for Cancer Treatment Development - MSN
BioAtla and Context Therapeutics Forge Strategic Agreement for Cancer Treatment Development - MyChesCo
Analyzing Bio-Techne Corp (TECH) After Recent Trading Activity - Knox Daily
BlackRock Capital Allocation Term Trust (NYSE:BCAT) Major Shareholder Saba Capital Management, L.P. Sells 33,209 Shares - Defense World
BioAtla out-licenses T cell therapy in $134 million deal - The Pharma Letter
(BTMD) Technical Pivots with Risk Controls - Stock Traders Daily
BioAtla licenses cancer drug candidate to Context Therapeutics By Investing.com - Investing.com Canada
BioAtla licenses cancer drug candidate to Context Therapeutics - Investing.com
Dawson James downgrades BioCardia Inc. (BCDA) stock to a Neutral - Knox Daily
Context Therapeutics signs second multimillion-dollar licensing deal in 3 months - The Business Journals
BlackRock Capital Allocation Term Trust (NYSE:BCAT) Major Shareholder Sells $245,706.93 in Stock - Defense World
SickKids names FCB Canada new AOR - Strategy Online
Context builds up bank of bispecific antibodies with up to $133M biobucks deal for BioAtla asset - Fierce Biotech
BioAtla licenses cancer drug candidate to Context Therapeutics - Investing.com India
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody - GlobeNewswire
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody - StockTitan
Massachusetts Financial Services Co. MA Has $741,000 Holdings in BioAtla, Inc. (NASDAQ:BCAB) - Defense World
Acadian Asset Management LLC Sells 80,157 Shares of BioAtla, Inc. (NASDAQ:BCAB) - Defense World
Benjamin Edwards Inc. Decreases Stake in Bank of America Co. (NYSE:BAC) - MarketBeat
BlackRock Capital Allocation Term Trust (NYSE:BCAT) Major Shareholder Saba Capital Management, L.P. Sells 15,894 Shares - Defense World
BioAtla, Inc. (NASDAQ:BCAB) Short Interest Down 6.3% in August - Defense World
BioAtla, Inc. (NASDAQ:BCAB) Short Interest Down 6.3% in August - MarketBeat
Analyzing Genocea Biosciences (NASDAQ:GNCA) and BioAtla (NASDAQ:BCAB) - Defense World
BioAtla (NASDAQ:BCAB) Stock Rating Reaffirmed by JMP Securities - Defense World
Balance Sheet Insights: BioAtla Inc (BCAB)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
BCAB’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
BioAtla reports promising Phase 2 trial results for cancer drug By Investing.com - Investing.com Canada
Head to Head Contrast: Genocea Biosciences (NASDAQ:GNCA) vs. BioAtla (NASDAQ:BCAB) - Defense World
BioAtla reports promising Phase 2 trial results for cancer drug - Investing.com
BioAtla reports promising Phase 2 trial results for cancer drug By Investing.com - Investing.com UK
BioAtla Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity with Manageable Tolerability among Heavily Pretreated Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) at the 2024 Euro - Yahoo Finance
JMP Securities Reiterates Market Outperform Rating for BioAtla (NASDAQ:BCAB) - MarketBeat
Examining BioAtla Inc (BCAB) more closely is necessary - US Post News
BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting - StockTitan
BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting - Yahoo Finance
BioAtla Inc (BCAB) Stock: Navigating Drops and Gains - The InvestChronicle
Should investors be concerned about BioAtla Inc (BCAB)? - US Post News
Companies Like BioAtla (NASDAQ:BCAB) Could Be Quite Risky - Yahoo Finance
Daily Market Movement: BioAtla Inc (BCAB) Sees a -2.75 Decrease, Closing at 1.77 - The Dwinnex
Short Interest in BioAtla, Inc. (NASDAQ:BCAB) Rises By 18.8% - MarketBeat
BioAtla to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Yahoo Finance
Stocks of BioAtla Inc (BCAB) are poised to climb above their peers - SETE News
Financial Fitness Check: Examining BioAtla Inc (BCAB)’s Key Ratios - The Dwinnex
Bioatla Inc Stock (BCAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):